SecBot SecBot
Biotech Drug Report Generated Jul 1, 2026

FIRDAPSE

CPRX·CATALYST PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized (FDA approval December 2018)
Why 4/10
FIRDAPSE is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout for this drug. The next hard catalyst for the stock is the Angelini Pharma acquisition closing (expected Q3 2026 at $31.50/share), which is a corporate M&A event, not a drug catalyst. Per the impact score rubric, an approved drug with no imminent new binary catalyst scores 3-5 regardless of revenue size or strategic importance.
Actionable Insight NEUTRAL

FIRDAPSE is a cash-generating approved product with patent protection into 2035, but CPRX stock is now primarily an acquisition-arbitrage vehicle: trading at ~$29.27 vs the $31.50 all-cash buyout by Angelini Pharma expected to close Q3 2026. The spread reflects deal-closing risk. There's no drug-specific binary catalyst; the thesis is purely M&A-driven from here.

Price Chart

Loading chart...

Executive Summary

FIRDAPSE (amifampridine phosphate) is Catalyst Pharmaceuticals' flagship product, the first and only FDA-approved treatment for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder. Approved in December 2018, it generated ~$358M in net product revenue in 2025 (17% YoY growth), with 2026 guidance of $435-450M. Patent settlements with Teva and Lupin block generic competition until 2035. However, the stock is now being acquired by Angelini Pharma for $31.50/share (~$4.1B all-cash), expected to close Q3 2026. With the drug already approved and no upcoming regulatory binary, FIRDAPSE itself is no longer a binary catalyst driver, the investment thesis has shifted to the buyout closing.

How It Works

FIRDAPSE is a potassium channel blocker that works at the connection point between nerves and muscles. In Lambert-Eaton myasthenic syndrome (LEMS), the immune system attacks these connection points, reducing the chemical signal (acetylcholine) that tells muscles to contract. FIRDAPSE blocks potassium channels in nerve endings, which prolongs the electrical signal and allows more of the muscle-contracting chemical to be released, thereby improving muscle strength.

Trial Status

FIRDAPSE was approved by the FDA in December 2018 for adults with LEMS, with subsequent label expansions for pediatric patients (6+) and higher dosing. Two pivotal Phase 3 placebo-controlled trials supported approval, demonstrating maintained muscle strength and improved patient-reported physical well-being. The drug is now the first-line recommended therapy for LEMS with a growing commercial footprint.

The Two-Sided Case

▲ Bull Case4
FIRDAPSE is the only FDA-approved, evidence-based treatment for LEMS, giving it a de facto monopoly in a defined rare-disease population with high patient need.
Product revenue continues to grow strongly: ~$358M in 2025 (17% YoY), with 2026 guidance of $435-450M (21-26% growth) driven by life-cycle management in Idiopathic and Cancer-Associated LEMS.
Patent protection extends to at least February 2035 via settlement agreements with Teva, Lupin, and Inventia, securing long-term market exclusivity.
The Angelini Pharma acquisition at $31.50/share (all-cash, ~$4.1B) was unanimously approved by both boards, expected to close Q3 2026, capping the stock with a guaranteed exit price.
▼ Bear Case5
The stock is now an acquisition-arbitrage position trading at a spread to the $31.50 buyout price, meaning there's limited upside and residual deal-closing risk (regulatory, shareholder, financing).
Jacobus Pharmaceuticals' Ruzurgi (amifampridine base) is approved for pediatric LEMS and prescribed off-label in adults, providing a lower-cost competitive alternative to FIRDAPSE.
FYCOMPA (perampanel), another Catalyst product, faces generic competition, which could pressure the company's overall financial profile during the deal process.
The stock's composite quant score is -71 (very bearish technically) and RSI-14 is 72.1 (overbought territory), suggesting limited near-term momentum.
Multiple analysts downgraded the stock after the acquisition announcement (Stephens to Equal-Weight, Citi and HC Wainwright to Neutral), reflecting the removal of upside beyond the deal price.

Upcoming Catalysts

  • Angelini Pharma acquisition closing, expected Q3 2026; the definitive agreement at $31.50/share all-cash is the primary stock catalyst
  • FIRDAPSE revenue growth trajectory as orphan-drug commercial execution continues; no specific clinical/regulatory readout dates remain for this approved drug

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CATALYST PHARMACEUTICALS, INC. DEFA14A CPRX ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 firdapsehcp.com3 angelinipharma.com4 ir.catalystpharma.com5 ir.catalystpharma.com6 fda.gov7 ir.catalystpharma.com8 drugs.com9 en.wikipedia.org10 statnews.com11 sec.gov